CAMK2G and hydrops fetalis: This was similar to the results of previous studies that demonstrated that, in the absence of CaMKII signals, CaN does not seem to contribute to abnormal cardiac remodeling, thus highlighting CaMKII and not CaN as a promising drug target to combat HF [16].